3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
All subjects in this study have previously been in an Idenix HCV study and received study
 drug for 3 consecutive days. Subjects who had received placebo in a previous Idenix study
 will not be enrolled in this study.

 In this study, researchers will try to find answers to these questions:

 -  How much (if any) hepatitis C virus is in your blood after stopping your Idenix study
 drug?

 -  Is your hepatitis C virus possibly resistant to treatment with the Idenix study drug or
 similar drugs?
The data obtained from this study will be used to further understand the long-term efficacy
 of Idenix DAAs used to treat HCV infection and to further understand HCV resistance to Idenix
 DAAs.
Inclusion Criteria:

 -  Read and signed the written informed consent form (ICF) after the nature of the study
 has been fully explained

 -  Have participated in an Idenix-sponsored study of an Idenix DAA

 -  Received at least 3 consecutive days of DAA treatment in an Idenix-sponsored study

 -  Agreed to comply with the visit schedule and laboratory tests

 Exclusion Criteria:

 -  Treatment with placebo only, in an Idenix sponsored study

 -  Antiviral treatment for HCV after participation in an Idenix sponsored study of an
 Idenix DAA